<div id="readability-page-1"><div><p><span>Anzalone Christopher Richard Chairman of the Board of Arrowhead Pharmaceuticals Inc [ARWR] filed a Form 4 on December 19, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:</span></p><div><table><tbody><tr><td><span>Date</span></td><td><span>12/17/25</span></td></tr><tr><td><span>Transaction</span></td><td><span>Surrender(1)</span></td></tr><tr><td><span>Shares</span></td><td><span>85,000</span></td></tr><tr><td><span>Price</span></td><td><span>$64.04</span></td></tr><tr><td><span>Value</span></td><td><span>$5,443,460</span></td></tr></tbody></table></div><p><span>Ending Holdings: 3,831,957 - Direct</span></p><ul><li><span>(1)</span></li><li><span>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</span></li></ul><p><span>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.</span></p><p><span>Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.</span></p><span> </span></div></div>

ARWR

<p>Anzalone Christopher Richard, Chairman of Arrowhead Pharmaceuticals Inc [ARWR], filed a Form 4 with the SEC on December 19, 2025, disclosing the surrender of 85,000 shares at $64.04 each, valued at $5,443,460. The surrender was to pay option exercise costs and/or resulting tax liability. His ending holdings are 3,831,957 shares directly.</p>

Chmn Anzalone Surrenders 85,000 Of Arrowhead Pharmaceuticals Inc [ARWR]